MSL
MDGL icon

Mackay Shields LLC’s Madrigal Pharmaceuticals MDGL Stock Holding History

Mackay Shields LLC’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,261
Closed -$733K – 1064
2021
Q1 		$733K Sell
6,261
-3,467
-36% -$404K 0.01% 1095
2020
Q4 		$1.08M Sell
9,728
-2,400
-20% -$293K 0.01% 1066
2020
Q3 		$1.44M Hold
12,128
– – 0.01% 903
2020
Q2 		$1.37M Buy
12,128
+200
+2% +$19.7K 0.01% 914
2020
Q1 		$796K Buy
11,928
+1,400
+13% +$117K 0.01% 1018
2019
Q4 		$960K Sell
10,528
-1,200
-10% -$116K 0.01% 1076
2019
Q3 		$1.01M Buy
11,728
+1,800
+18% +$169K 0.01% 1103
2019
Q2 		$1.04M Buy
9,928
+6,967
+235% +$746K 0.01% 1114
2019
Q1 		$371K Buy
2,961
+400
+16% +$49.7K ﹤0.01% 1239
2018
Q4 		$289K Buy
2,561
+161
+7% +$24.9K ﹤0.01% 1256
2018
Q3 		$514K Buy
+2,400
New +$602K ﹤0.01% 1000

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Mackay Shields LLC's MDGL Position: Q2 2021 in Review

Mackay Shields LLC sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2021, closing a stake of 6,261 shares — an estimated $733K sold.

Mackay Shields LLC first reported a position in MDGL in Q3 2018 and held it in 11 quarters. The position peaked at $1.44M in Q3 2020. 151 funds tracked by Wall St. Rank hold MDGL as of Q2 2021.

  • Mackay Shields LLC reported no remaining Madrigal Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 6,261 Madrigal Pharmaceuticals shares in Q2 2021, an estimated $733K.
  • Mackay Shields LLC first reported a position in Madrigal Pharmaceuticals in Q3 2018 and held it in 11 quarters.
  • Mackay Shields LLC's Madrigal Pharmaceuticals position peaked at $1.44M in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.